SomatiCA statistics

To access cutting-edge analytics on consensus tools, life science contexts and associated fields, you will need to subscribe to our premium service.


Citations per year

Citations chart

Popular tool citations

chevron_left Tumor purity and heterogeneity estimation Somatic CNA detection chevron_right
Popular tools chart

Tool usage distribution map

Tool usage distribution map

Associated diseases

Associated diseases

SomatiCA specifications


Unique identifier OMICS_06950
Name SomatiCA
Software type Package/Module
Interface Command line interface
Restrictions to use None
Operating system Unix/Linux, Mac OS, Windows
Programming languages R
License GNU General Public License version 2.0
Computer skills Advanced
Version 1.4.0
Stability Stable
methods, IRanges, GenomicRanges, DNAcopy, R(>=2.14.0), foreach, doParallel, lars, rebmix, sn
Maintained Yes



Add your version



  • person_outline Hongyu Zhao <>

Publication for SomatiCA

SomatiCA in publications

PMCID: 5225790
PMID: 27958595
DOI: 10.14639/0392-100X-1093

[…] (1) mutazione germinale del gene smarcb1 o del gene lztr1; (2) ampia delezione all'interno del cromosoma 22 (con perdita del gene nf2 e dell'allele intatto smarcb1 o lztr1); e (3) mutazione somatica dell'allele intatto del gene nf2 [meccanismo conosciuto come "four hits": "quadrupla alterazione" (su entrambi gli alleli dei due geni swnts/nf2), con tre passaggi consecutivi]. negli ultimi […]

PMCID: 4335967
PMID: 25729424
DOI: 10.3332/ecancer.2015.511

[…] number of ilp clinical trials that used melphalan. he also pointed out that this technique is now accepted by a number of national bodies., dr ruggerio ridolfi, of immunoterapia e terapia cellulare somatica meldola, gave a talk entitled ‘planning ipilimumab therapy in a single institution’. he identified the immunotherapy unit and the pharmacy unit of the romagna cancer centre as the focus […]

PMCID: 4096026
PMID: 25075214
DOI: 10.3332/ecancer.2014.440

[…] has already been successful with breast, non-small-cell lung carcinoma, and pancreas cancers, and is in phase iii trials for melanoma., ruggero ridolfi from the immunoterapia e terapia cellulare somatica ior meldola started the second half of the third session with a switch back to strategic issues in his talk about implementing ‘drug days’ in an italian hospital to cut costs and save waste […]

To access a full list of publications, you will need to upgrade to our premium service.

SomatiCA institution(s)
Program of Computational Biology and Bioinformatics, Yale University, New Haven, CT, USA; Department of Genetics, Yale University, New Haven, CT, USA; Department of Neurosurgery, Yale University, New Haven, CT, USA; Department of Biostatistics, Yale University, New Haven, CT, USA
SomatiCA funding source(s)
Supported by the NIH grant R01 GM59507.

SomatiCA reviews

star_border star_border star_border star_border star_border
star star star star star

Be the first to review SomatiCA